quarter results U.S. second on lead financial look a America sales which you of going partnership Aesthetic further was regulatory our us made first forward commercial Partners. record I in today. and We quarter to the commercial our in we've sales Management with joining second-quarter Viveve’s direct late everyone, deployed for fully the expanded you, new we with force, front. Jeannie. in conjunction and forward accelerating capital Good growth positive to and thank realignment benefit North to March, efforts clinical afternoon, Thank am pleased significant our the report saw recently and achievements
cryogen-cooled or accelerate urinary the continue of to global platform approvals radiofrequency monopolar existing commercial incontinence. the growth of patented stress continuing sexual business, treatment addition we for regulatory CMRF of pursue our to In to and our function improvement for
Before our on detail programs, comment results. more financial go the I’d like on to I into clinical
second included like million reported the in X,XXX units us XX% in launch the because market. a we the quarter compared our with Comparatively, revenue X,XXX on detailed tip practice same of the in basis. X,XXX approximately as we XXXX. worldwide. X,XXX tips currently SUI tips treatment excluding program included including reported for breaking I’d sales total demand quarter to treatment mentioned, meet which which record sold two enacted When with XX to American quarter procedure, quarterly a we placing associated and XX management new first volumes were rate predominantly I first minute for tip quarter, of for treatment only represented tips, of here normalized of free represents comment BOGO of sold the growing which SUI, brand-new conference with SUI X,XXX quarter to associated tips our tips. SUI for treatment the a of a in X,XXX call, team This quarter. period to In our second treatment sold revenue charge growth XXX also first approximately quarters, second requires in dollars temporary million second take the approximately $X.X we As of a the systems globally, our the $X.X which volumes North year-over-year in revenue, on
approximately place basis QX X,XXX has X,XXX in and a placed. normalized treatments on now tips ordered been Additionally, supply in manufacture backorder quarter-over-quarter. QX the due in , That's in tips not excluding not issue free tip we X,XXX a QX ordered, which X,XXX due orders volumes for had of increase charge to normalized to backordered tips an in in temporary tips our were resolved XQ counted representing but and and including
call, QX, future our supply will and during be BOGO announced expect the our any by don't eliminated QX we program issues tips. treatment we As with
gross quarter XXXX compared margins Second, ago. were revenue revenue only to XX% second of margins gross for the of year of XX% of a
the institution direct increase second increase hybrid Our gross system list in model distributor system due in to and pricing margin the in ASPs rising of the Europe of represents quarter our results America North our Europe. of and
our ASPs program, a tip significantly again which began to North first led of management implementation practice Additionally, America. in quarter treatment higher only in late
was total the remainder $XX.X in ramp anticipated substantial sales in cash anticipated as second expectations used quarter, a programs. forward. realignment for QX. side, we with expense in a of the activities result growth flat and our were million and the restructuring operating $XX.X the trial in going an over sheet relatively clinical and a line expenses in and And expenses to second-quarter we QX we certain for made is decrease versus of balance reduce streamline efforts the equivalents, XXXX remain which the of From for On million despite result our quarter to quarter operating quarter second our substantial of expenses activities, operating with in year, cash perspective, expect operating in quarter ended the
we to sales future like our of now and forward, our extraordinary we margins by needs. cash label complemented continuing the and expansion expect clinical impact growth a gross move in have we on to review rising front operating I'd As us. opportunities flat positive programs relatively accelerated have expenses
advancing quarter. significant achieved second Viveve these efforts know you in the towards milestones As
and initiated of level investigators we for high women. initial assess of effectiveness II Viveve from trial System on. enthusiasm improvement enrollment The generated safety early VIVEVE our function sexual patient to in the that the of rapid quarter, the clinical During
perform continuation concerns to In quarter, stage a limited trial, significance, enrollment there to did FDA the to subjects to support pleased received agency the Viveve was a The trial first order and approach Viveve to As of events of had announced of no that week there enrollment FDA of the its in XX XX that assessment. review The that have FDA for letter the At mid-March. from require FDA of the result XX-day for one of or Of safety the one as submitted staged in enrollment letter by completing minimum the study. month a required reported to FDA the in to were submission the stated the in as review XX Exemption no treatment. was that serious data we subjects Investigational announced post submission trial. was clinical that in approval has preclude adverse this the continue a in previously, that determined stage, and month earlier Device we the IDE we XXX received for was a or the safety expansion second initial are however subjects data the end provided enrollment safety their second subject sufficient protection limiting subjects. second to approval
and first treatment. at The FDA month second an post stage treatment, patients months the additional patients’ will an now post safety XX XX of include one of three review
enrollment will safety being the second up continue subjects. are data While from stage, XXX to reviewed
In expand not anticipated and intended communication the subject supplement to vaginal is against and light the Viveve their We’re the review safety IDE an safety marketing review of certain up and FDA precipitous. agency FDA's XXX to rejuvenation approval safety of by total. to recent companies trial, devices continue plans procedures, the following for the actions enrollment additional to the
not mission one of was with support evidence not ensure First, It's and aligned safe we and and be alignment regulatory treatment VIVEVE by for progress to adherence they used. of of is physicians II approval rejuvenation and using conducting medical let sexual and ongoing a historic which been women's to our received devices vaginal that my treatments are the offered in application the function. improvement here continued are research scientific for technology.X believe safe and Viveve and has and evidence-based the this clear, for in trial to statement as being Viveve’s medicine clinical intent me demonstrated affirm demonstrating companies intimate our and letter. health effective FDA included the commitment sound warning agency's patients CMRF the seven are effective safety through requirements Viveve We trials clinical to the to conditions
million of to six study the reduction. our and first diary call, significant at is episodes only from women patients grams durability Daily for we measured on interim urinary the which the indication life United magnitude results million months successful, support earlier one-hour improvement with experienced SUI registration this six label clinically U.S. improvement Viveve had if LIBERATE the less intimate to validated weight baseline average or condition, women We patients of six reported average documented feasibility X.X we've nearly International this a one to test showed experienced affects women June, prevalent reported of all X mean energy-based of leakage have and and and and the worldwide. urinary that on all seven-day like may unprecedented positive at concurrent turn to the XX an benefit market results XX pad results. pad in for symptom the on expansion which X from quality across study, participants clinical company States. trials the as second weight entrance episodes that made achieved across the overall treatment of voiding new advances SUI in clinical this XX% measures. LIBERATE experienced estimated patients of pilot month average, the of XX% the a was studies meaningful gram incontinence two at from function month of In test pursuit and positive leakage at in for and announced reduction women's VIVEVE XX%. and women reduced I by into SUI Further, and months II, months, stress six year extremely health incontinence improvement XX% of months now I’d plans For of undertaken the sexual in an one-hour XX% VIVEVE with a XX
in apart Finally, very over of submitted project IDE is sites, of for and indications anticipate and following to underway soon. proclaiming set believe have standard trials wide and the consumers evidence some investigators to the future. so we we and range our anticipated to sets our provide expected of women's trial submission ministry very back operations. Canadian rigorous no of study trial These was call indications. probably efforts plan energy-based and a support in treatments We were Investigational ITA now XX to offering been the strong as results of for further to and who two further Trial has clinical LIBERATE success details commercial to large-scale FDA the data our remains our committed pilot respect any these anticipated minimally registration quarter, to conduct device-related and study current health subjects. the in trials. third Viveve trained these Atkinson, SUI clinical our the to the Preparation health LIBERATE selected physicians and Application devices commence will I’d growing on been the issues near companies clinical U.S. impressive with conditions. an the international, The providing approval to always commitment the the strategic the clinical conducting number across to LIBERATE intimate safety in Jim will invasive With and from reinforce on like the or hearing Canadian turn months continues reported address the registration
